The popularity of Sildenafil initially sparked a boom for major pharmaceutical companies, however recent shifts present a uncertain outlook for shareholders. Off-patent alternatives are reducing profits, and persistent https://neilsvlo131571.widblog.com/96060018/the-blue-pill-and-pharma-a-risky-play